Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$5.43
-3.2%
$5.08
$3.55
$11.16
$440.41M1.132.81 million shs3.96 million shs
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
$1.10
$1.09
$0.26
$1.28
$116.26M1.61957,342 shsN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$9.25
-0.5%
$9.16
$7.44
$10.90
$458.01M-0.1267,357 shs200,660 shs
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$8.52
-1.2%
$7.64
$4.20
$9.76
$465.87M1.87646,443 shs364,216 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
0.00%-4.90%-5.89%-9.35%-27.70%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.00%0.00%0.00%0.00%0.00%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
0.00%-0.54%-10.80%+1.09%+7.31%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
0.00%-1.50%+6.50%+16.23%+83.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Altimmune, Inc. stock logo
ALT
Altimmune
2.2877 of 5 stars
3.51.00.00.01.93.30.6
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
N/AN/AN/AN/AN/AN/AN/AN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
1.139 of 5 stars
2.10.00.00.03.22.50.6
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
3.0077 of 5 stars
4.60.00.00.04.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
3.00
Buy$20.20272.01% Upside
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.00
N/AN/AN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
2.25
Hold$11.3322.52% Upside
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
3.11
Buy$22.29161.57% Upside

Current Analyst Ratings Breakdown

Latest SCTL, TBPH, ZVRA, and ALT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/14/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00
4/3/2025
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
3/18/2025
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
3/14/2025
Altimmune, Inc. stock logo
ALT
Altimmune
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/13/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$23.00 ➝ $25.00
3/13/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $22.00
3/13/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
3/12/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$18.00
3/12/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
3/12/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00
(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$20K22,020.55N/AN/A$2.75 per share1.97
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
$94.64M1.23N/AN/A$0.56 per share1.96
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$65.27M7.09N/AN/A$4.28 per share2.16
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$40.59M11.48N/AN/A$1.71 per share4.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.45M-$1.26N/AN/AN/A-199,076.92%-55.81%-50.60%8/6/2025 (Estimated)
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
-$13.27M-$0.15N/AN/A-14.03%-23.82%-8.80%N/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$55.19M-$1.18N/A26.43N/A-78.18%-24.79%-13.43%8/4/2025 (Estimated)
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
-$46.05M-$1.90N/A42.60N/A-342.63%-159.54%-51.50%8/12/2025 (Estimated)

Latest SCTL, TBPH, ZVRA, and ALT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million
5/13/2025Q1 2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
-$0.21-$0.06+$0.15-$0.06$16.96 million$20.40 million
5/8/2025Q1 2025
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
-$0.11-$0.27-$0.16-$0.27$28.08 million$15.39 million
3/11/2025Q4 2024
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
-$0.39-$0.67-$0.28-$0.67$8.93 million$12.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
N/AN/AN/AN/AN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
16.87
16.87
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
0.01
1.07
0.86
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/A
4.97
4.97
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
0.84
2.88
2.88

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
87.15%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
99.10%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
35.03%

Insider Ownership

CompanyInsider Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
4.10%
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
7.60%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
6.90%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5081.11 million68.21 millionOptionable
Societal CDMO, Inc. stock logo
SCTL
Societal CDMO
258105.69 million97.66 millionOptionable
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
35950.00 million45.78 millionOptionable
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2054.68 million52.10 millionOptionable

Recent News About These Companies

Zevra Therapeutics (NASDAQ:ZVRA) Upgraded at Wall Street Zen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Altimmune stock logo

Altimmune NASDAQ:ALT

$5.43 -0.18 (-3.21%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$5.43 0.00 (0.00%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Societal CDMO stock logo

Societal CDMO NASDAQ:SCTL

Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally. The company provides end-to-end services, such as formulation development focusing on complex formulations, reformulation, physical characterization, and excipient compatibility; analytical methods development which offers a range of analytical testing capabilities, including product testing, ICH stability, method development and validation, chromatography and spectroscopy equipment, stability chambers, and microbial testing; and pharmaceutical manufacturing that provides milling, blending, compression, spray and rotary granulation, particle and bead coating, encapsulation, liquids, lyophilization, and sterile fill and finish services. It also offers regulatory support, including handling communications with the food and drug administration (FDA) and seek consultation and guidance for client FDA meetings and responses; and pharmaceutical packaging and logistics, as well as smaller-scale primary and secondary packaging, labeling and kitting options suited for clinical trial materials and development packaging needs across dosage forms. The company was formerly known as Recro Pharma, Inc. and changed its name to Societal CDMO, Inc. in March 2022. Societal CDMO, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.

Theravance Biopharma stock logo

Theravance Biopharma NASDAQ:TBPH

$9.25 -0.05 (-0.54%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$9.16 -0.09 (-0.97%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Zevra Therapeutics stock logo

Zevra Therapeutics NASDAQ:ZVRA

$8.52 -0.10 (-1.16%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$8.55 +0.03 (+0.35%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.